Comparison of the Impact of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management Trial on Prescribing Patterns: A Time-Series Analysis

Abstract

Spanish

French

Background:

The AFFIRM (Atrial Fibrillation Follow-Up Investigation of Rhythm Management) trial demonstrated that rate control and rhythm control strategies result in similar survival and quality of life for patients with atrial fibrillation (AF). Because of superior safety and lower cost, rate control is now the recommended strategy (or the management of most elderly, high-risk AF patients.

Objective:

To determine the extent to which the AFFIRM trial results have been adopted into actual practice.

Methods:

We conducted a time-series analysis of 3 population-based cohorts of patients with AF who were 66 years of age or older in Pennsylvania and Ontario. We stratified patients in Ontario by socioeconomic status (SES) and examined changes in quarterly prescription rates for rate control and rhythm controlling medications as well as cardioversion procedures before and after publication of the AFFIRM trial.

Results:

The publication of the AFFIRM trial resulted in statistically significant reductions in the use of rhythm controlling medications in all 3 cohorts (p < 0.01). The magnitude of these changes in the non-low SES Canadian cohort was approximately 1% per quarter and was greater than the magnitude observed in the other cohorts (p < 0.001). The use of cardioversion procedures also decreased in all study regions (p < 0.01). In contrast, AFFIRM publication was also associated with a small increase in the use of rate controlling medications in Canada (p < 0.01) but not in the US (p = 0.23).

Conclusions:

Publication of the AFFIRM trial resulted in small but statistically significant changes in the care of patients with AF.

Keywords

atrial fibrillation practice patterns prescribing

Get full access to this article

View all access options for this article.

References

, Hylek

, Phillips

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001; 285: 2370–5.

Falk

. Atrial fibrillation. N Engl J Med 2001; 344: 1067–78.

Marshall

, Levy

, Vidaillet

Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann Intern Med 2004; 141:653–61. 141/9/653 [pii]

Waldo

. Management of atrial fibrillation: the need for AFFIRMative action. AFFIRM investigators. Atrial Fibrillation Follow-up Investigation of Rhythm Management. Am J Cardiol 1999; 84: 698–700.

Wyse

, Waldo

, DiMarco

A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825–33.

Van Gelder

, Hagens

, Bosker

A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834–40.

Carlsson

, Miketic

, Windeler

Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41: 1690–6.

Hohnloser

, Kuck

, Lilienthal

Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356: 1789–94.

Opolski

, Torbicki

, Kosior

Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004; 126: 476–86.

10.

Steinberg

, Sadaniantz

, Kron

Analysis of cause-specific mortality in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Circulation 2004; 109:1973–80. 10.1161/01.cir.0000118472.77237.fa

11.

Fuster

, Ryden

, Cannom

ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257–354.

12.

Snow

, Weiss

, LeFevre

Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2003; 139: 1009–17.

13.

Pharmaceutical Assistance Contract for the Elderly Act. 62 P.S. 2901–2908. www.pacode.com/secure/data/006/006toc.html (accessed 2006 May 16).

14.

Fischer

, Avorn

Economic implications of evidence-based prescribing for hypertension: can better care cost less?

JAMA 2004; 291: 1850–6.

15.

Solomon

, Finkelstein

, Katz

, Mogun

, Avorn

Underuse of osteoporosis medications in elderly patients with fractures. Am J Med 2003; 115: 398–400.

16.

Fisher

, Whaley

, Krushat

The accuracy of Medicare's hospital claims data; progress has been made, but problems remain. Am J Public Health 1992; 82: 243–8.

17.

Fowles

, Lawthers

, Weiner

, Garnick

, Petrie

, Palmer

. Agreement between physicians' office records and Medicare Part B claims data. Health Care Financ Rev 1995; 16: 189–99.

18.

Glynn

, Monane

, Gurwitz

, Choodnovskiy

, Avorn

Agreement between drug treatment data and a discharge diagnosis of diabetes mellitus in the elderly. Am J Epidemiol 1999; 149: 541–9.

19.

Romano

, Mark

. Bias in the coding of hospital discharge data and its implications for quality assessment. Med Care 1994; 32: 81–90.

20.

Williams

, Young

A summary of studies on the quality of health care adminstrative databases in Canada. In: Goel

, Williams

, Anderson

eds. Patterns of health care in Ontario. The ICES Practice Atlas. Ottawa: Canadian Medical Association, 1996: 339–45.

21.

Juurlink

, Mamdani

, Kopp

, Laupacis

, Redelmeier

. Drug–drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289: 1652–8.

22.

Bell

, Redelmeier

. Mortality among patients admitted to hospitals on weekends as compared with weekdays. N Engl J Med 2001; 345: 663–8.

23.

Mamdani

, Tu

, van Walraven

, Austin

, Naylor

. Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy. CMAJ 2000; 162: 1421–4.

24.

Crighton

, Mamdani

, Upshur

. A population based time series analysis of asthma hospitalisations in Ontario, Canada: 1988 to 2000. BMC Health Serv Res 2001; 1: 7.

25.

Choudhry

, Soumerai

, Normand

, Ross-Degnan

, Laupacis

, Anderson

. Warfarin prescribing in atrial fibrillation: the impact of Physician, patient, and hospital characteristics. Am J Med 2006; 119: 607–15.

26.

Choudhry

, Anderson

, Laupacis

, Ross-Degnan

, Normand

, Soumerai

. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ 2006; 332: 141–5.

27.

Kokotailo

, Hill

. Coding of stroke and stroke risk factors using International Classification of Diseases, revisions 9 and 10. Stroke 2005; 36: 1776–81.

28.

Frost

, Vestergaard

Caffeine and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr 2005; 81: 578–82.

29.

Juurlink

, Mamdani

, Lee

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543–51.

30.

Schneeweiss

, Seeger

, Maclure

, Wang

, Avorn

, Glynn

. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154:854–64. 10.1093/aje/154.9.854

31.

Pindyck

, Ruvinfeld

. Econometric models and economic forecasts. Boston: Irwin/McGraw-Hill, 1998.

32.

Williams

, Miller

. Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session. J Am Coll Cardiol 2002; 40: 1–18.

33.

Austin

, Mamdani

. Impact of the pravastatin or atorvastatin evaluation and infection therapy—Thrombolysis in Myocardial Infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada. Circulation 2005; 112: 1296–300.

34.

, Mamdani

, Jacka

, Forde

, Rothwell

, Tu

. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ 2003; 168: 553–7.

35.

Udell

, Fischer

, Brookhart

, Solomon

, Choudhry

. Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res 2006; 21: 765–71.

36.

Greer

. The state of the art versus the stale of the science. The diffusion of new medical technologies into practice. Int J Technol Assess Health Care 1988; 4: 5–26.

37.

Jackson

, Peterson

, Vial

. A community-based educational intervention to improve antithrombotic drug use in atrial fibrillation. Ann Pharmacother 2004; 38:1794–9. Epub 28 Sept 2004. DOI 10.1345/aph.1E152

38.

Dartnell

, Allen

, McGrath

, Moulds

. Prescriber guidelines improve initiation of anticoagulation. Med J Aust 1995; 162: 70–3.

39.

Gaughan

, Dolan

, Wilk-Rivard

Improving management of atrial fibrillation and anticoagulation in a community hospital. Jt Comm J Qual Improv 2000; 26: 18–28.

40.

Grimshaw

, Shirran

, Thomas

Changing provider behavior: an overview of systematic reviews of interventions. Med Care 2001; 39: 112–45.

41.

Jamtvedt

, Young

, Kristoffersen

, O'brien

, Oxman

. Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2006:CD000259.

42.

Alter

, Chong

, Austin

Socioeconomic status and mortality after acute myocardial infarction. Ann Intern Med 2006; 144: 82–93.

43.

Alter

, Naylor

, Austin

, Tu

. Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med 1999; 341: 1359–67.

44.

Minkler

, Fuller-Thomson

, Guralnik

. Gradient of disability across the socioeconomic spectrum in the United States. N Engl J Med 2006; 355:695–703. DOI 10.1056/NEJMsa044316

45.

Goldman

, Smith

. Socioeconomic differences in the adoption of new medical technologies. Am Econ Rev 2005; 95: 234–7.

46.

Kaul

, Armstrong

, Chang

Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I. Circulation 2004; 110: 1754–60.

47.

Alexander

, Peterson

, Granger

Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trial. J Am Coll Cardiol 1998; 32: 2023–30.

48.

Majumdar

, McAlister

, Soumerai

. Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States. Am J Med 2003; 115: 467–72.